Search

Your search keyword '"Rivaroxaban"' showing total 22,600 results
Start Over Descriptor "Rivaroxaban"
22,600 results on '"Rivaroxaban"'

8. PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PRESTIGE-AF)

Author

Wuerzburg University Hospital, Julius-Maximilians University, Medical University of Graz, University of Liverpool, King's College London, Hospital Universitari Vall d'Hebron Research Institute, University of Bordeaux, Azienda Ospedaliera di Perugia, Aalborg University, STROKE ALLIANCE FOR EUROPE, University Hospital Heidelberg, Imperial College Healthcare NHS Trust, Alfried Krupp Krankenhaus, and University Hospital, Bordeaux

Published
2024

14. Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting

Author

Zhejiang University, Ningbo No.2 Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Taizhou Enze Hospital, Taizhou First People's Hospital, Boston Scientific Corporation, and Hongkun Zhang, MD, Chief of Department of Vascular Surgery

Published
2024

34. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Author

Joglar, José, Chung, Mina, Armbruster, Anastasia, Benjamin, Emelia, Chyou, Janice, Cronin, Edmond, Deswal, Anita, Eckhardt, Lee, Goldberger, Zachary, Gopinathannair, Rakesh, Gorenek, Bulent, Hess, Paul, Hlatky, Mark, Hogan, Gail, Ibeh, Chinwe, Indik, Julia, Kido, Kazuhiko, Kusumoto, Fred, Link, Mark, Linta, Kathleen, McCarthy, Patrick, Patel, Nimesh, Patton, Kristen, Perez, Marco, Piccini, Jonathan, Russo, Andrea, Sanders, Prashanthan, Streur, Megan, Thomas, Kevin, Times, Sabrina, Tisdale, James, Valente, Anne, Van Wagoner, David, and Marcus, Gregory

Subjects
ACC/AHA Clinical Practice Guidelines, acute coronary syndrome, alcohol, anticoagulants, anticoagulation agents, antiplatelet agents, apixaban, atrial fibrillation, atrial flutter, cardioversion, catheter ablation, coronary artery disease, coronary heart disease, dabigatran, edoxaban, exercise, heart failure, hypertension, idarucizumab, left atrial appendage occlusion, myocardial infarction, obesity, percutaneous coronary intervention, pulmonary vein isolation, risk factors, rivaroxaban, sleep apnea, stents, stroke, surgical ablation, thromboembolism, warfarin, Humans, United States, Atrial Fibrillation, American Heart Association, Cardiology, Thromboembolism, Risk Factors
Abstract

AIM: The 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE: Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation and the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.

Published
2024

35. Challenges to Laboratory Monitoring of Direct Oral Anticoagulants

Author

Qiao, Jesse and Tran, Minh-Ha

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hematology, Patient Safety, Humans, Administration, Oral, Anticoagulants, Drug Monitoring, Factor Xa Inhibitors, Blood Coagulation Tests, anticoagulants, bleeding reversal, coagulation, direct oral anticoagulants, direct thrombin inhibitor, rivaroxaban, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

Direct oral anticoagulants (DOACs) exert anticoagulation effect by directly inhibiting Factor Xa (rivaroxaban, apixaban, and edoxaban) or thrombin (dabigatran). Though DOACs are characterized by fixed-dose prescribing and generally do not require routine laboratory drug-level monitoring (DLM), circumstances may arise where the DLM may aid in clinical decision-making, including DOAC dose adjustment, anticoagulant class change, or decisions to withhold or administer reversal agents. We review the current literature that describes high-risk patient groups in which DLM may be beneficial for improved patient anticoagulation management and stewardship. The review also summarizes the limitations of conventional coagulation testing and discuss the emerging utility of quantitative methods for routine and rapid emergent evaluation of DOAC drug levels-in particular, the Anti-Xa activity to detect Factor Xa Inhibitors (rivaroxaban, apixaban, and edoxaban). Both technical and regulatory barriers to widespread DLM implementation are limiting factors to further clinical research that must be overcome, in order to propose universal DOAC DLM strategies and provide clinical-laboratory correlation to formally classify high-risk patient groups.

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results